The World Health Organization published a report highlighting imbalances in clinical genomics research: over 80% of registered genomic studies occur in high-income countries while under 5% take place in low- and middle-income countries. The WHO traced the rise in genomic trials to reduced sequencing costs and national investments, but said infrastructure and funding gaps leave many regions underrepresented. The report also found skewed disease prioritization and limited LMIC leadership on multinational trials. WHO recommended targeted capacity investments, regional cooperation models, and policy actions to broaden participation and ensure genomic advances translate more equitably into clinical care.